Influence of digoxin-like immunoreactive factor on late complications in patients with diabetes mellitus

URN to cite this document:: urn:nbn:de:bvb:355-epub-220399
DOI to cite this document:: 10.5283/epub.22039

Straub, R. H. ; Elbracht, R. ; Krämer, Bernhard K. ; Roth, M. ; Palitzsch, K.-D. ; Schölmerich, J.

Preview

PDF
(1MB)

Date of publication of this fulltext: 08 Sep 2011 06:36

Alternative links to fulltext:Pubmed

Details

Preview

Export bibliographical data

Abstract

The aim of this study was to compare the intensity of typical late complications in diabetic patients (n = 65, 28 type I, 37 type II) who were not on glycoside drugs with low vs. high serum levels of digoxin-like immunoreactive factor (DLIF: group I, n = 42, DLIF < or = the detection limit of 0.2 ng ml-1; and group II, n = 23, mean +/- SEM: 1.17 +/- 0.31 [0.25-4.96] ng ml-1). For detection of ...